CADTH launches call for patient input on oral edaravone

Feb 9 2022 – The Canadian Agency for Drugs and Technology in Health (CADTH) today posted a call for patient input on oral edaravone. This is a key milestone and a hopeful indicator for the Canadian ALS community. ALS Canada will be preparing a submission that reflects the diversity of perspectives and experiences of people living with ALS from across the country – and we are inviting you to add your voice. If you have direct experience with oral edaravone through the clinical trial and are interested in sharing your experience with us, please contact us at advocacy@als.ca.

Additionally, thank you to all community members who participated in our November 2021 CADTH survey that informed our submission about AMX0035. Your responses will have twice the impact, because we’ll be referencing them for the oral edaravone submission, too! Your input continues to help us ensure that issues of importance to the ALS community are considered by decision-makers at CADTH, who ultimately recommend whether public drug plans should cover the drug if it is approved by Health Canada.

We will continue to provide updates as we learn more about oral edaravone. You can learn more about how drugs become accessible to Canadians by visiting our blog post on this topic.